2023 World Conference on Lung Cancer (Posters)-EP13.05. Real-world Efficacy of PD-1/PD-L1 Inhibitors in Patients with Advanced Pulmonary Neuroendocrine Carcinoma

EP13.05. Real-world Efficacy of PD-1/PD-L1 Inhibitors in Patients with Advanced Pulmonary Neuroendocrine Carcinoma - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the real-world efficacy of PD-1/PD-L1 inhibitors in patients with advanced pulmonary neuroendocrine carcinoma (PNEC). A total of 203 patients who received PD-1/PD-L1 inhibitors between January 2019 and December 2021 were analyzed. The majority of patients had small-cell lung cancer (81.3%), followed by large-cell neuroendocrine carcinoma (6.4%) and other unspecified PNEC (12.3%).<br /><br />In the entire cohort, the objective response rate (ORR) was 49.3% and the disease control rate (DCR) was 83.7%. The median progression-free survival (PFS) was 6.3 months and the median overall survival (OS) was 13.1 months. There were no significant differences in PFS or OS among patients with different types of PNEC.<br /><br />In the first-line treatment, ORR, DCR, median PFS, and OS were 65.6%, 92.8%, 7.0 months, and 15.5 months, respectively. In the second-line or later line setting, ORR was 23.1%, DCR was 69.2%, median PFS was 4.0 months, and median OS was 9.4 months. Patients who received immunotherapy plus small-molecule antiangiogenic therapy had a significantly greater PFS compared to those who received immunotherapy alone or with chemotherapy.<br /><br />There was a trend for superior PFS and OS in patients without liver metastasis compared to those with liver metastasis. However, this trend was not observed in patients without brain metastasis.<br /><br />Overall, PD-1/PD-L1 inhibitors were effective in patients with advanced PNEC in the real-world setting, regardless of the histology. The efficacy of first-line immunochemotherapy was also noteworthy. The addition of small-molecule antiangiogenic therapy to immunotherapy in second-line treatment showed a better survival trend. Further studies are needed to confirm these findings.

Asset Subtitle

Yun Fan

Meta Tag

Speaker Yun Fan

Topic SCLC & Neuroendocrine Tumors: NETs

Keywords

PD-1/PD-L1 inhibitors

pulmonary neuroendocrine carcinoma

real-world efficacy

small-cell lung cancer

large-cell neuroendocrine carcinoma

objective response rate

disease control rate

progression-free survival

overall survival

immunotherapy